---
title: "MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289054333.md"
description: "MediciNova announced it received a Notice of Allowance from the USPTO for a patent covering the use of MN-166 (ibudilast) in combination with anti-PD-1 immune checkpoint inhibitors for treating glioblastoma. This development strengthens the company's intellectual property portfolio as it advances its strategy for developing combination therapies."
datetime: "2026-06-08T12:02:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289054333.md)
  - [en](https://longbridge.com/en/news/289054333.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289054333.md)
---

# MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

On June 8, 2026, in La Jolla, California, MediciNova, Inc., a biopharmaceutical company listed on NASDAQ (MNOV) and the Tokyo Stock Exchange (Code Number: 4875), announced receiving a Notice of Allowance from the U.S. Patent and Trademark Office. This notice pertains to a patent application involving the utilization of ibudilast (MN-166) alongside an immune checkpoint inhibitor, specifically an anti-PD-1 antibody, for treating glioblastoma. The allowance of this patent is anticipated to reinforce the company's intellectual property position as it advances its strategy for developing combination therapies.

### Related Stocks

- [MNOV.US](https://longbridge.com/en/quote/MNOV.US.md)
- [4875.JP](https://longbridge.com/en/quote/4875.JP.md)

## Related News & Research

- [MediciNova says US patent office allows ibudilast–anti-PD-1 combo claims for glioblastoma treatment](https://longbridge.com/en/news/291279545.md)
- [Dr. Reddy's registers PD-1 inhibitor in South Africa for recurrent or metastatic nasopharyngeal carcinoma](https://longbridge.com/en/news/294653513.md)
- [Clinuvel benchmarks vitiligo market as JAK inhibitor efficacy challenges NB-UVB standard of care](https://longbridge.com/en/news/294281005.md)
- [RARE: Record Q2 revenue and upcoming gene therapy launches position the company for 2027 profitability](https://longbridge.com/en/news/294883644.md)
- [Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation For Lx2020](https://longbridge.com/en/news/294966104.md)